SIRT1 and myeloid sarcoma: (31, 32) found that phosphorylated SIRT1 (p-SIRT1) and H3K9me3 are possible biomarkers for MS relapse, and SIRT1 and H3K9me3 potentially predict the response to glatiramer acetate (GA, a widely used drug in patients with MS) therapy.